Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 4.75B P/E - EPS this Y 240.50% Ern Qtrly Grth 2,897.20%
Income 30.57M Forward P/E 45.63 EPS next Y 59.60% 50D Avg Chg 12.00%
Sales 890.53M PEG -0.08 EPS past 5Y - 200D Avg Chg 45.00%
Dividend N/A Price/Book 12.06 EPS next 5Y -357.00% 52W High Chg -14.00%
Recommedations 2.20 Quick Ratio 1.81 Shares Outstanding 165.88M 52W Low Chg 113.00%
Insider Own 0.54% ROA 1.83% Shares Float 108.46M Beta 0.39
Inst Own 99.95% ROE 6.70% Shares Shorted/Prior 9.23M/10.66M Price 29.20
Gross Margin 51.34% Profit Margin 3.43% Avg. Volume 1,634,129 Target Price 25.28
Oper. Margin 12.58% Earnings Date Oct 31 Volume 1,707,063 Change 0.90%
About ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

ACADIA Pharmaceuticals Inc. News
05:55 AM Are ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?
10/08/24 Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09/23/24 Catherine Owen Adams Succeeds Steve Davis as CEO of Acadia Pharmaceuticals
09/03/24 High Growth Tech Stocks To Watch In September 2024
08/29/24 Implied Volatility Surging for ACADIA Pharmaceuticals (ACAD) Stock Options
08/28/24 Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
07:04 AM Ryan Reynolds Announces More to Parkinson’s® Campaign
05:47 AM Shareholders Can Be Confident That ACADIA Pharmaceuticals' (NASDAQ:ACAD) Earnings Are High Quality
08/08/24 ACADIA Pharmaceuticals Second Quarter 2024 Earnings: Beats Expectations
08/07/24 Acadia Pharmaceuticals to Participate in the Canaccord Genuity 44th Annual Growth Conference
08/07/24 Biotech Stocks: Why Acadia Pharma And Others Are Feeling 'Growing Pains'
08/07/24 Acadia (ACAD) Q2 Earnings Beat, Product Sales Drive Revenues
08/06/24 Acadia Pharmaceuticals (ACAD) Beats Q2 Earnings and Revenue Estimates
08/06/24 Acadia: Q2 Earnings Snapshot
08/06/24 Acadia Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operating Overview
08/03/24 Analysts Expect ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) To Breakeven Soon
07/30/24 Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
07/24/24 Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2024
07/18/24 Clinical Data from Open-Label Extension LILAC-1™ and LILAC-2™ Studies Evaluating Long-Term Safety and Efficacy of DAYBUE™ (trofinetide) in Patients with Rett Syndrome Published in Med
06/21/24 Why Is ACADIA Pharmaceuticals Inc (ACAD) One of the Best Debt Free Halal Stocks According to Hedge Funds?
ACAD Chatroom

User Image BobBijawk Posted - 11 hours ago

$ACAD downsider look when the news breaks on aquisition .

User Image Liberia Posted - 14 hours ago

$ACAD

User Image Downsiderisk Posted - 2 days ago

$ACAD Mylesss of a brain hasn’t contributed any useless information since he’s been on this thread. He’s the Joe Biden of Stocktwits! Arguably the King of Twits!

User Image Mylessss Posted - 2 days ago

$ACAD Ignore Downsiderisk, man's working in Macdonalds to cover his short every week! Hence, his opinion is INVALID!!

User Image Downsiderisk Posted - 2 days ago

$ACAD here’s the news Raylin It went up .37 cents and still under $15 a share. This stock has been such a disaster that people will latch onto any news they think will turn this titanic. It’s over people! Give up the BS already people! It’s exhausting watching you all squirm over nothing!

User Image raylin Posted - 3 days ago

$ACAD $IRWD $IOVA $AUPH All had a nice recovery around 1. No news. Any ideas on the cause?

User Image Downsiderisk Posted - 3 days ago

$ACAD Zeus and his Canada News. This guy will grab on to any news because his portfolio has died and he’s mortgaged his home for this dumpster of a stock. Give it up Zeus!

User Image zeustony88 Posted - 3 days ago

$ACAD Need Canada news soon and Downsideclown back to cave for winter.

User Image BobBijawk Posted - 3 days ago

$ACAD toke it up acad. Rhett syndrome US market is forecasted to grow around 8% per year. Add in europe Canada and Asia your looking at roughly a 15% per year jump in dayblue revenues.

User Image Downsiderisk Posted - 3 days ago

$ACAD enough said! Funny, the graph actually looks like a sinking ship! Kind of like Bobs marriage after his wife found out he was gay.

User Image Mylessss Posted - 3 days ago

$ACAD

User Image Sunman8 Posted - 3 days ago

$ACAD Revenue is increasing, profit is increasing, cash position is increasing, over 10 years of exclusivity with patent for lead drug, clinical trials are brewing, new CEO at the helm with fresh ideas..all this good stuff happening and share price keeps falling. Go figure. Let’s get this one sold to big pharma for about $5B so they can trim the fat with consolidation and make it even more profitable. Depressing to see the share price get kicked to the ground day after day.

User Image BobBijawk Posted - 3 days ago

$ACAD downsiders gotta trade alot to feed his wife

User Image Leomessi2024 Posted - 4 days ago

$ACAD Bought 1K at 14.40 and quickly see a profit. Acadia used to be 20 to $30 when it had no drugs no income and now so many in the pipelines waiting for FDA to approve and it still sits in the bottom ?

User Image Downsiderisk Posted - 4 days ago

$ACAD Bob the chances of Acadia acquiring a company is about the same as you acquiring a women! Two losers!

User Image BobBijawk Posted - 4 days ago

$ACAD just moved into oversold territory. 5.80 dollars per share in revenue. Trading at 2.5 times annual sales per share. Aquistion would pay minimum 4 times annual sales or 23 per share. Aquiring company will cut all expenses and absorb operations into existing staff making their actual earnings potential up to 10 times what we see on our books. so dont get it twisted two approved drugs with at least 7 years of exclusivity with revenues close to 1 billion with mutliple intl approvals coming for dayblue.

User Image HorizonBull Posted - 4 days ago

$ACAD added 1k 14.43

User Image Mylessss Posted - 4 days ago

$ACAD

User Image BobBijawk Posted - 4 days ago

$ACAD downsider

User Image BobBijawk Posted - 4 days ago

$ACAD downsider is so broke he can only post at the library.

User Image Downsiderisk Posted - 5 days ago

$ACAD here’s an update on Bob and Richie…current status…..

User Image raylin Posted - 5 days ago

$ACAD Need Bakers to start a BO rumor from a somewhat credible source.

User Image Ham1198 Posted - 5 days ago

$ACAD will close RED. Again. But don’t worry it’s undervalued

User Image Mylessss Posted - 5 days ago

$ACAD https://hedgefollow.com/stocks/ACAD Hedgies loaded more > we load more!

User Image BobBijawk Posted - 5 days ago

$ACAD downsider is a frequent rider of the short bus.

User Image coloradoriley Posted - 5 days ago

Trends with No Friends, 10-8-2024 Amer Sports Accelerates To An All-Time High, ACADIA Pharmaceuticals Falls To 2-Year Low Click the link to view today's 52W highs and lows sorted by followers on @Stocktwits: https://trendswithnofriends.stocktwits.com/p/10-8-2024 cc @howardlindzon $AS $ACAD $SPY $QQQ $IWM

User Image Downsiderisk Posted - 5 days ago

$ACAD who cares San Tush! You’re going to argue over 30 cents when this stock can’t hold $15 😂😂😂🤡🤡🤡

User Image SanKish Posted - 6 days ago

$ACAD why is this showing 14.90 AH on stocktwits but not on my brokerage platform?

User Image GI197845 Posted - 6 days ago

$ACAD Some would say, it would say this downward trend is a buying opportunity, because it should go up this month due to Canadian Daybue approval.

User Image GI197845 Posted - 6 days ago

$ACAD Inducements in the ole'corn hole!

Analyst Ratings
Citigroup Buy Aug 8, 24
UBS Buy Aug 8, 24
HC Wainwright & Co. Buy Aug 8, 24
Needham Buy Aug 7, 24
Cantor Fitzgerald Overweight Aug 7, 24
RBC Capital Outperform Aug 7, 24
Morgan Stanley Equal-Weight Aug 7, 24
Morgan Stanley Overweight Jul 12, 24
BMO Capital Outperform Jun 27, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
DAVIS STEPHEN CEO CEO Jan 06 Sell 29.96 3,732 111,811 96,521 01/09/24
Teehan Brendan EVP, COO, Head of Co.. EVP, COO, Head of Commercial Jan 06 Sell 29.96 731 21,901 30,949 01/09/24
KIM AUSTIN D. EVP,General Counsel,.. EVP,General Counsel, Secretary Jan 06 Sell 29.96 590 17,676 46,901 01/09/24
Kihara James Principal Accounting.. Principal Accounting Officer Dec 15 Sell 28.30 2,000 56,600 11,025 12/15/23
Teehan Brendan EVP, COO, Head of Co.. EVP, COO, Head of Commercial Nov 17 Sell 22.64 4,960 112,294 30,393 11/21/23
Schneyer Mark C. EVP, Chief Financial.. EVP, Chief Financial Officer Nov 17 Sell 22.64 5,108 115,645 20,486 11/21/23
Kihara James Principal Accounting.. Principal Accounting Officer Nov 17 Sell 22.64 1,985 44,940 13,025 11/21/23
KIM AUSTIN D. EVP,General Counsel,.. EVP,General Counsel, Secretary Oct 05 Sell 21.96 16,369 359,463 45,857 10/06/23
DAVIS STEPHEN CEO CEO Oct 05 Sell 21.96 51,563 1,132,323 89,131 10/06/23
Kihara James Principal Accounting.. Principal Accounting Officer Sep 15 Sell 25.88 2,000 51,760 10,778 09/19/23
Schneyer Mark C. EVP, Chief Financial.. EVP, Chief Financial Officer Aug 21 Sell 28.997 10,000 289,970 15,682 08/23/23
DAVIS STEPHEN CEO CEO Jul 14 Option 20.77 100,000 2,077,000 136,695 07/18/23
DAVIS STEPHEN CEO CEO Jul 14 Sell 30.04 100,000 3,004,000 36,695 07/18/23
DAVIS STEPHEN CEO CEO Jul 11 Sell 25.03 71,602 1,792,198 36,695 07/13/23
Brege Laura Director Director Jun 12 Sell 24.868 4,500 111,906 13,502 06/14/23
Schneyer Mark C. EVP, Chief Financial.. EVP, Chief Financial Officer Jun 08 Sell 25.02 974 24,369 22,824 06/12/23
Schneyer Mark C. EVP, Chief Financial.. EVP, Chief Financial Officer Jun 08 Option 0 1,893 23,798 06/12/23
BAKER BROS. ADVISORS LP Director Director May 22 Buy 25.22 896,522 22,610,285 39,317,673 05/24/23
BAKER BROS. ADVISORS LP Director Director May 22 Option 17.01 25,000 425,250 38,620,261 05/24/23
Kihara James Principal Accounting.. Principal Accounting Officer May 17 Sell 22.5 5,947 133,808 11,144 05/19/23
Schneyer Mark C. EVP, Chief Financial.. EVP, Chief Financial Officer May 17 Sell 22.5 15,310 344,475 21,905 05/19/23
Teehan Brendan EVP, COO, Head of Co.. EVP, COO, Head of Commercial May 17 Sell 22.5 14,869 334,552 24,356 05/19/23
KIM AUSTIN D. EVP,General Counsel,.. EVP,General Counsel, Secretary Apr 29 Sell 21.18 917 19,422 25,513 05/02/23
Teehan Brendan EVP, COO, Head of Co.. EVP, COO, Head of Commercial Apr 29 Sell 21.18 548 11,607 9,487 05/02/23
Teehan Brendan EVP, COO, Head of Co.. EVP, COO, Head of Commercial Apr 29 Option 0 1,567 10,035 05/02/23
DAVIS STEPHEN CEO CEO Apr 29 Sell 21.18 7,806 165,331 108,297 05/02/23
DAVIS STEPHEN CEO CEO Apr 29 Option 0 15,625 116,103 05/02/23
Kihara James Principal Accounting.. Principal Accounting Officer Apr 07 Sell 18.14 523 9,487 5,197 04/11/23
Teehan Brendan EVP, COO, Head of Co.. EVP, COO, Head of Commercial Apr 05 Sell 18.16 1,751 31,798 8,468 04/07/23
Kihara James Principal Accounting.. Principal Accounting Officer Apr 05 Sell 18.16 701 12,730 4,231 04/07/23
Schneyer Mark C. EVP, Chief Financial.. EVP, Chief Financial Officer Apr 05 Sell 18.16 1,916 34,795 7,477 04/07/23
DAVIS STEPHEN CEO CEO Apr 05 Sell 18.16 8,582 155,849 100,478 04/07/23
KIM AUSTIN D. EVP,General Counsel,.. EVP,General Counsel, Secretary Apr 05 Sell 18.16 1,456 26,441 23,425 04/07/23
Kihara James Principal Accounting.. Principal Accounting Officer Feb 23 Sell 18.78 350 6,573 2,923 02/27/23
Schneyer Mark C. EVP, Chief Financial.. EVP, Chief Financial Officer Feb 23 Sell 18.78 577 10,836 4,118 02/27/23
DAVIS STEPHEN CEO CEO Feb 23 Sell 18.78 3,851 72,322 91,727 02/27/23
KIM AUSTIN D. EVP,General Counsel,.. EVP,General Counsel, Secretary Feb 23 Sell 18.78 803 15,080 20,108 02/27/23
Teehan Brendan EVP, COO, Head of Co.. EVP, COO, Head of Commercial Feb 23 Sell 18.78 461 8,658 5,195 02/27/23
BAKER BROS. ADVISORS LP Director Director Jan 12 Option 5.22 30,000 156,600 38,484,981 01/17/23
DAVIS STEPHEN CEO CEO Jan 06 Sell 17.13 3,904 66,876 84,633 01/10/23
Teehan Brendan EVP, COO, Head of Co.. EVP, COO, Head of Commercial Jan 06 Sell 17.13 532 9,113 4,549 01/10/23
KIM AUSTIN D. EVP,General Counsel,.. EVP,General Counsel, Secretary Jan 06 Sell 17.13 589 10,090 18,697 01/10/23
Stankovic Srdjan R. President President Oct 15 Sell 15.81 1,326 20,964 56,831 10/18/22
DAVIS STEPHEN CEO CEO Oct 15 Sell 15.81 2,804 44,331 79,009 10/18/22
Schneyer Mark C. EVP, Chief Financial.. EVP, Chief Financial Officer Jun 08 Option 0 1,893 3,995 06/10/22
Schneyer Mark C. EVP, Chief Financial.. EVP, Chief Financial Officer Jun 08 Sell 17.91 653 11,695 3,342 06/10/22
DAVIS STEPHEN CEO CEO Apr 29 Sell 18.18 5,483 99,681 75,875 05/03/22
Stankovic Srdjan R. President President Apr 29 Sell 18.18 2,865 52,086 55,188 05/03/22
KIM AUSTIN D. EVP,General Counsel,.. EVP,General Counsel, Secretary Apr 29 Sell 18.18 894 16,253 16,742 05/03/22
Teehan Brendan EVP, COO, Head of Co.. EVP, COO, Head of Commercial Apr 29 Sell 18.18 552 10,035 3,437 05/03/22